Tredegar Q3 2024 break-even ongoing ops; completes Terphane sale for $78M enterprise value

TREDEGAR CORP

2025-Q3 EPS reported $0.24

Q3 2024 net income from ongoing ops $0.2M ($0.01/share) vs loss of $5.1M ($0.15) in Q3 2023.
GAAP net loss $3.9M ($0.11/share) vs $50.4M loss year-ago.
Aluminum Extrusions EBITDA $6.2M (up 21%); PE Films EBITDA $5.9M (up from $4.0M).
Closed sale of Terphane on Nov 1 for $60M cash; enterprise value $78M; additional $7M expected from escrow.
Net leverage ratio reduced to 1.2x pro forma from 2.3x; USITC trade case vote negative, coalition evaluating options.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.